🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you to the advocates who rallied today in Chicago for #AccessNow! Your dedication, along with all those taking action, tells CMSGov that we won’t back down in fighting for equitable access to these life-changing treatments. People with early Alzheimer’s can’t wait.

Secretary Xavier Becerra Why does CMSGov continue to block access to FDA-approved Alzheimer’s treatments that would slow the progression of the disease? This would give families #MoreTime with their loved ones as just family, not make them caregivers!

Our advocates are turning the Ways and Means Committee and Ways and Means Democrats health subcommittee hearing purple to show their support for #AccessNow to FDA-approved Alzheimer’s treatments!

THANK YOU to the advocates who rallied outside the CMS office in Chicago today! Together, our voices were heard as we demanded #AccessNOW and #MoreTime 📣#AlzIllinois

Secretary Xavier Becerra Why are you refusing to cover drugs that could help treat Alzheimer’s disease? The VA is covering them. Do you think their scientists are wrong? #moretime

“Broadly restricting coverage for Alzheimer's treatments is a devastating blow to the patients and caregivers relying on new innovations." Thank you, Committee Chair Rep. Jason Smith, for standing with people living with early Alzheimer’s and their families who deserve #AccessNow.

“Thank you for the opportunity to share what access to innovation means to me: It means #MoreTime with my wife, my kids and my grandkids.” - Tony Gonzales, living with MCI at 48, testifies at the health subcommittee hearing for #AccessNow to FDA-approved Alzheimer’s drugs.

.Rep. Mike Kelly is right. CMSGov saying accelerated approval ≠ full approval, and denying coverage based on this, sets a precedent for Medicare to deny coverage for ALL drugs approved through this pathway, including drugs for cancer. #AccessNow

Thank you, Rep. Brad Wenstrup, for speaking up for people living with early Alzheimer’s. The choice to take an FDA-approved treatment should be between the individual, their loved ones, and their doctor. We need #AccessNow.

Exactly. Thank you Rep. Brad Wenstrup! We need #AccessNow so people living with Alzheimer’s have #MoreTime! #ENDALZ

Secretary Xavier Becerra Does this include providing full CMS coverage for FDA approved Alzheimer’s drugs? #AccessNow #MoreTime #ENDALZ

"I've demonstrated what’s meaningful & necessary in my life. What's meaningful & necessary in yours? What if this were you? The government shouldn't be having this conversation with me. This should be between myself & my physician. Period.” Well said, Tony Gonzales. #AccessNow

“What is reasonable and necessary is that we need this to go between the patient and the doctor.” - Tony Gonzales on how CMSGov’s unfair decision to block FDA-approved Alzheimer’s drugs denies those with early Alzheimer’s choice and #MoreTime. #AccessNow

For those who would like a deeper look into very misunderstood events regarding FDA's accelerated approval of Aduhelm, I recommend reading this piece by Dr. Wang.

Thank you, Nanette D. Barragán, for your continued leadership and support for #AccessNow to FDA-approved Alzheimer’s treatments. And thank you for joining us today at our rally at HHS.gov headquarters to demand CMSGov reverse their unfair decision.

Proud to join Alzheimer's Association National Capital Area to demand #AccessNow to FDA-Approved Alzheimer's treatments. This is personal for me & everyone who has someone with this disease.   My bill, the Access to Innovative Treatments Act, can help patients get FDA-approved treatments sooner. We need action now!

This Alzheimer’s and Brain Awareness Month, I continue to fight to stop harmful policies delaying access to treatment for Alzheimer’s patients. The Administration must reverse course and provide access to life-saving treatments as quickly as possible.

Just announced: The FDA has approved donanemab for the treatment of people living with early symptomatic Alzheimer’s disease. We celebrate donanemab’s approval, as more treatment options mean a greater opportunity for #MoreTime. bit.ly/3XIyyvf